title: [New drugs against parasitic diseases].
abstract: The gap in the antiparasitic armamentarium is still not filled in 2006 and few original and useful drugs were marketed in the last decade. Against malaria, artemether combined with lumefantrine is adopted as first line therapy in a majority of endemic countries but still not available in France and several european countries. As its tolerance and efficacy are satisfactory, atovaquone-proguanil, is taking a major place for prevention and treatment in travellers. Liposomal amphothericin B and miltefosine extended the treatment of visceral leishmaniasis. Nitazoxanide and triclabendazole may be usefull in cryptosoridiosis or giardiasis and fasciolasis, respectively.
authors: UMR 8076 CNRS, faculté de pharmacie, université de Paris-Sud XI, 92290 Châtenay-Malabry. philippe.loiseau@cep.u-psud.fr
authors: Philippe M
authors: PM
authors: Loiseau
authors: Jacques
authors: J
authors: Le Bras
mesh_terms: D000962:Antimalarials / Q000627:therapeutic use; D053626:Atovaquone / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy; D010272:Parasitic Diseases / Q000188:drug therapy*
chemical_list: D000962:Antimalarials; D053626:Atovaquone